The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW OKs Add’l Indications for Keytruda, Tecentriq, Hemlibra, and More
December 25, 2018
-
REGULATORY After Settling on October 2019 Re-Pricing, When Will Govt Reveal New Drug Prices?
December 21, 2018
-
REGULATORY PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
-
REGULATORY Govt to Pare Drug Prices by 2.4% in October 2019 Ad-Hoc Re-Pricing
December 19, 2018
-
BUSINESS Takeda Likely to Make NYSE Debut on Christmas Eve
December 19, 2018
-
REGULATORY Ministers Agree on Ad-Hoc Drug Re-Pricing in October 2019, 29 Billion Yen Saving in State Coffers
December 18, 2018
-
COMMENTARY LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
-
BUSINESS Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
-
BUSINESS Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
December 14, 2018
-
BUSINESS Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
December 14, 2018
-
REGULATORY Govt to Tap R&D Tax Credit System to Push Research on Pediatric Use, Superbug Fight
December 13, 2018
-
REGULATORY Chuikyo Adopts Outline of 2019 Drug Price Revision for Sales Tax Hike
December 13, 2018
-
BUSINESS Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018
-
REGULATORY MHLW to Offer Free Rubella Shots to Men Aged 39-56
December 12, 2018
-
REGULATORY Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
-
REGULATORY Big Improvement in Single-Product, Single-Price Transaction Rate in April-Sept.; Over 90% with Dispensing Pharmacy Chains
December 11, 2018
-
REGULATORY R&D Tax Credit Refit Taking Shape; Open Innovation Scheme Likely to Cover Research Commissioned to Big Firms
December 10, 2018
-
REGULATORY JPMA Official Renews Call for Use of “Specified Clinical Research” Data in Application Dossiers
December 7, 2018
-
REGULATORY Chuikyo Agrees on 3 ICER Thresholds for “Tiered” CEA Price Adjustment Model; Industry Hearing Slated by Year-End
December 6, 2018
-
BUSINESS Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…